OTLK

MKT CAP:$13M

Outlook Therapeutics, Inc.

Market Cap

$13M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.29-$0.37 (-56.53%)

Apr 23, 2026

Company Details

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulati...

CEO

Robert Charles Jahr

IPO Date

Jun 14, 2016

Website

www.outlooktherapeutics.com

Key Metrics TTM

Revenue

$1M

+730.9% YoY

Net Income

-$62M

EPS (Diluted)

-$1.85

Free Cash Flow

-$52M

Revenue / Share

$0.06

Gross Margin

-0.0%

Operating Margin

-4744.3%

Net Margin

-4416.2%

FCF Margin

-3666.7%

P/S

9.1x

P/E

—

Earnings Reports

Q4 2025

Dec 19, 2025

-$91.8K-154.0%EPS -$0.52

Q3 2025

Aug 14, 2025

$2MEPS -$0.55

Q2 2025

May 15, 2025

$0EPS -$1.50

Q1 2025

Feb 14, 2025

$0EPS $0.72

FY 2024

Dec 27, 2024

$0EPS -$4.06

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$13M
Q2 22	$0	$0	-$19M
Q3 22	$0	$0	-$17M
Q4 22	$0	$0	-$14M
Q1 23	$0	$0	-$16M
Q2 23	$0	$0	-$7M
Q3 23	$0	$0	-$18M
Q4 23	$0	-$11.2K	-$12M
Q1 24	$0	-$28.2K	-$10M
Q2 24	$0	-$28.2K	-$19M
Q3 24	$0	-$28.7K	-$20M
Q4 24	$170.1K	$85.1K	-$23M
Q1 25	$0	-$28.8K	-$22M
Q2 25	$0	-$29.1K	-$12M
Q3 25	$2M	$1M	-$16M
Q4 25	-$91.8K	-$1M	-$17M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	75.4x	—
Q1 25	75.4x	—
Q2 25	75.4x	0.6x
Q3 25	7.7x	—
Q4 25	9.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$11M	-$11M
Q2 22	-$14M	-$14M
Q3 22	-$21M	-$21M
Q4 22	-$10M	-$10M
Q1 23	-$9M	-$9M
Q2 23	-$8M	-$8M
Q3 23	-$13M	-$13M
Q4 23	-$13M	-$13M
Q1 24	-$13M	-$13M
Q2 24	-$19M	-$19M
Q3 24	-$20M	-$20M
Q4 24	-$17M	-$17M
Q1 25	-$11M	-$11M
Q2 25	-$17M	-$17M
Q3 25	-$12M	-$12M
Q4 25	-$12M	-$12M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-7.3%
Q2 22	—	+49.8%
Q3 22	—	+48.4%
Q4 22	—	+4.1%
Q1 23	—	+19.3%
Q2 23	—	-63.8%
Q3 23	—	+6.6%
Q4 23	—	-10.9%
Q1 24	—	-34.2%
Q2 24	—	+177.0%
Q3 24	—	+7.8%
Q4 24	—	+85.0%
Q1 25	—	+109.3%
Q2 25	—	-34.6%
Q3 25	—	-11.8%
Q4 25	-154.0%	-25.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$1M	—
Q2 22	$4M	—
Q3 22	$1M	—
Q4 22	$1M	—
Q1 23	$1M	—
Q2 23	$1M	—
Q3 23	$1M	—
Q4 23	$1M	—
Q1 24	$1M	—
Q2 24	$1M	—
Q3 24	$1M	—
Q4 24	$1M	826.3%
Q1 25	$4M	—
Q2 25	$2M	—
Q3 25	$2M	111.7%
Q4 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 22	$10M	$3M	—
Q2 22	$12M	$7M	—
Q3 22	$11M	$6M	—
Q4 22	$9M	$5M	—
Q1 23	$10M	$6M	—
Q2 23	$544.9K	$6M	—
Q3 23	$11M	$7M	—
Q4 23	$5M	$8M	—
Q1 24	$5M	$6M	—
Q2 24	$14M	$5M	—
Q3 24	$11M	$8M	—
Q4 24	$13M	$10M	—
Q1 25	$10M	$12M	$298
Q2 25	$4M	$8M	—
Q3 25	$7M	$10M	—
Q4 25	$6M	$10M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$14M	$0	$14M
Q1 22	$70M	$0	$70M
Q2 22	$58M	$0	$58M
Q3 22	$26M	$0	$26M
Q4 22	$17M	$0	$17M
Q1 23	$52M	$0	$52M
Q2 23	$44M	$0	$44M
Q3 23	$34M	$0	$34M
Q4 23	$23M	$0	$23M
Q1 24	$10M	$0	$10M
Q2 24	$47M	$0	$47M
Q3 24	$32M	$0	$32M
Q4 24	$15M	$0	$15M
Q1 25	$6M	$0	$6M
Q2 25	$8M	$0	$8M
Q3 25	$9M	$0	$9M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	9M	+11.7%	+54.6%
Q2 22	11M	+16.4%	+45.3%
Q3 22	11M	+0.7%	+30.9%
Q4 22	11M	-3.8%	+25.9%
Q1 23	11M	+7.2%	+20.9%
Q2 23	13M	+12.9%	+17.2%
Q3 23	13M	+0.1%	+16.5%
Q4 23	13M	+1.3%	+22.7%
Q1 24	13M	0.0%	+14.4%
Q2 24	14M	+9.7%	+11.2%
Q3 24	25M	+78.5%	+98.3%
Q4 24	19M	-27.2%	+42.5%
Q1 25	24M	+30.6%	+86.2%
Q2 25	31M	+27.4%	+116.4%
Q3 25	37M	+19.7%	+45.1%
Q4 25	25M	-31.1%	+37.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	9
Q2 22	$0	9
Q3 22	$0	9
Q4 22	$0	17
Q1 23	$0	17
Q2 23	$0	17
Q3 23	$0	17
Q4 23	$0	24
Q1 24	$0	24
Q2 24	$0	24
Q3 24	$0	24
Q4 24	$7.4K	23
Q1 25	$0	23
Q2 25	$0	23
Q3 25	$65.4K	23
Q4 25	-$5.4K	17

Revenue / Employee